Second-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trial

Goss, G. D.Cobo, M.Lu, S.Syrigos, K.Lee, K. H.Goker, E.Georgoulias, V.Li, W.Isla, D.Morabito, A.Min, Y. J.Ardizzoni, A.Jian, H.Yu, Y.Bender, S.Cseh, A.Felip, E.2025-01-072025-01-072019-11-011556-0864https://hdl.handle.net/10668/24371enlung SCCafatiniberlotinibsecond-lineSecond-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trialconference outputopen access10.1016/j.jtho.2019.09.1651556-1380http://www.jto.org/article/S1556086419334938/pdf494945000074